Arecor Limited is pleased to announce its participation at PEPTalk 2019’s Protein Science Week. This leading international conference and one of the largest annual gatherings of over 1,300 protein science researchers in the world, will be held between January 14-18, 2019, at the Hilton Hotel, San Diego Bayfront, San Diego, California, USA.
Arecor participates in PepTalk 2019’s Protein Science week in San Diego, CA, USA
Arecor is the UK-based leading formulation technology company, focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides enabling the improved treatment of diabetes and other conditions.
Arecor’s Chief Scientific Officer, Dr Jan Jezek, will present a talk at PEPTalk 2019’s Protein Science Week entitled ‘Novel Biopharmaceutical Compositions to Reduce the Rate of Aggregation’ in the ‘PROTEIN AGGREGATION AND EMERGING ANALYTICAL TOOLS’ part of the conference on Thursday, 17th January 2019. In addition, Dr Jezek will chair a series of presentations relating to the emerging analytical tools for detection of protein aggregation at the concluding session of the conference on Friday, 18th January 2019.
Aggregation is one of the main problems affecting the stability of high-value therapeutic protein products, such as those used in oncology, autoimmune diseases or metabolic disorders, because aggregated proteins may result in a negative immune response or they may affect the therapeutic efficacy. Therefore, the levels of aggregated protein in biopharmaceutical compositions must be maintained to a minimum.
Arecor has developed a proprietary formulation technology, Arestat™, that enables superior biopharmaceutical products in which the protein aggregation is kept to a minimum. Application of the technology allows development of safe and convenient products that would otherwise not be achievable using conventional approaches to formulation, for example via enabling products that do not require refrigerated storage.
Dr Jezek’s PEPTalk presentation will summarise some of the key principles behind the technology as well as several case studies demonstrating the capability of the technology in developing differentiated biopharmaceutical product profiles.
Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: “I am delighted to have the opportunity to present at PEPTalk this year. Having participated at this conference several times in the past, I fully endorse it as an excellent forum at which to learn about the latest advances in biopharmaceutical development and at which to hold a number of very interesting discussions with many experts in the field”.
“Arecor keeps making considerable progress in the development of highly differentiated products through the application of our proprietary formulation technology. Participation at events such as PEPTalk allows us to keep up-to-date with the latest developments in the biopharmaceutical industry and receive constructive feedback on our technology and product strategy.”
Arecor Limited is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Arecor's product portfolio also includes:
· Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
· Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices,
· Stable aqueous glucagon for emergency and artificial pancreas use, and
· A series of undisclosed pre-clinical programmes.
In addition, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
Arecor has significant experience and a proven track record in applying the ArestatTM formulation technology platform to deliver superior biopharmaceutical product profiles across a broad range of proteins, peptides and vaccines.
About Arecor’s Patent Portfolio
Arecor’s technology is protected by 28 patent families, including 26 granted patents. Arecor has been exploiting its technology in partnerships with pharmaceutical companies, successfully developing superior product profiles, including stable high-concentration antibodies with low viscosity, reformulations of lyophilised or freeze-dried products into stable liquids or stable vaccines that can be used outside the cold chain.
Advancing today's therapies to enable healthier lives.